Learn Mode

GILD - Gilead Sciences Inc

137

$140.27

$0.90 (0.646%)

4/1/26, 1:37 PM

Score

3.60/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

GILD

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$173.02B

Industry

Biotechnology

EPS (TTM)

$6.79

P/E (TTM)

20.33

Div & Yield

$3.28 (2.34%)

FCF Payout Ratio

43.77%

P/S (TTM)

5.88

P/B

7.62

Diluted Shares

1.25B

Ex-Dividend

2026-03-13

Next Earnings

04-23

Forward P/E

15.38

Payout Ratio

47.54%

P/FCF (TTM)

18.72

FCF Yield

5.34%

Earnings Yield

4.92%

52 Week Range

Score Card

Explore Scores Tab

3.60

Good

Gilead Sciences Inc has grown revenue at 2.4% over the past year, which suggests sales are increasing. Also, it has a free cash flow margin of 31.4%, which suggests the company is very profitable.

Valuation Model

Key Score

2.00

Bad

Management

5.00

Very Good

Growth

4.00

Good

Profitability

2.00

Bad

Fin. Health

3.00

Average

Dividends

5.00

Very Good

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

3 new filings were in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-30 17:59:52

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-27 16:03:17

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 18:40:06

Form ARS

Unknown Form Type

Filed on 2026-03-20 16:01:42

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-20 16:01:13

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-03-20 16:00:50

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-17 18:56:30

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-17 18:14:00

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-16 16:06:49

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-16 16:06:06

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:45:40

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:42:04

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$189.00

34.7%

Avg:

$161.06

14.8%

Low:

$119.18

-15.0%

(% change is relative to the current stock price: $140.27)

Analyst Recommendations

Go to Analyst Tab

4.05

Good

26%

Strong Buy (10)

53%

Buy (20)

21%

Hold (8)

Sell (0)

Strong Sell (0)

About

Website
https://www.gilead.com/
Address
333 Lakeside Dr, Foster City CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=882095

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.

IPO Date

1992-01-22

Industry

Biotechnology

Total Employees

17,000

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

GILD - Gilead Sciences Inc

137

$140.27

$0.90 (0.646%)

3.60/5

Stock Unlock

Stock Profile

Score Card

Good

Insider Transactions

Market News

Form 4

Filed on 2026-03-30 17:59:52

Form 144

Filed on 2026-03-27 16:03:17

Form SCHEDULE 13G/A

Filed on 2026-03-26 18:40:06

Form ARS

Filed on 2026-03-20 16:01:42

Form DEFA14A

Filed on 2026-03-20 16:01:13

Form DEF 14A

Filed on 2026-03-20 16:00:50

Form 4

Filed on 2026-03-17 18:56:30

Form 4

Filed on 2026-03-17 18:14:00

Form 144

Filed on 2026-03-16 16:06:49

Form 144

Filed on 2026-03-16 16:06:06

Form 4

Filed on 2026-03-12 16:45:40

Form 4

Filed on 2026-03-12 16:42:04

Financials

Price Targets

34.7%

14.8%

-15.0%

Analyst Recommendations

About

Similar Stocks